Welcome to our dedicated page for Royalty Pharma Plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma Plc stock.
Royalty Pharma plc (Nasdaq: RPRX) is a biopharmaceutical royalty company that frequently announces transactions, portfolio updates and financial results, making its news flow particularly relevant for investors following royalty-based business models in healthcare. Founded in 1996, the company describes itself as the largest buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry, with a portfolio of royalties on more than 35 commercial products and numerous development-stage therapies.
News about Royalty Pharma often centers on new royalty acquisitions and funding agreements. Recent press releases have described transactions such as acquiring remaining royalty interests in Roche’s Evrysdi, purchasing a royalty interest in Alnylam’s AMVUTTRA from Blackstone Life Sciences, and securing royalty interests in Nuvalent’s neladalkib and zidesamtinib. The company also reports synthetic royalty funding agreements, including a deal with Denali Therapeutics based on future net sales of tividenofusp alfa and a funding agreement with Teva for the anti-IL-15 antibody TEV-‘408 for vitiligo and celiac disease.
Royalty Pharma’s news feed additionally includes quarterly financial results, Portfolio Receipts updates, capital deployment figures, debt offerings, dividend declarations and participation in investor conferences. The company highlights clinical and regulatory milestones across its royalty portfolio, such as FDA approvals, Phase 3 trial initiations and pivotal data readouts for therapies like daraxonrasib, litifilimab, pelacarsen and other late-stage candidates.
Investors and observers who follow RPRX news can use these updates to track how the royalty portfolio is evolving, which therapeutic areas are gaining exposure, and how capital is being allocated across approved and investigational products. Regular news also provides insight into Royalty Pharma’s views on the royalty funding market, its use of non-GAAP liquidity measures, and its approach to shareholder returns through dividends and share repurchases.
Royalty Pharma has announced a $2.025 billion strategic funding partnership with MorphoSys to facilitate its $1.7 billion acquisition of Constellation Pharmaceuticals. This agreement includes an upfront payment of $1.425 billion, milestone payments of up to $150 million, and up to $350 million in Development Funding Bonds. Royalty Pharma will acquire future royalties from the blockbuster drug Tremfya, with 2020 sales reaching $1.347 billion, and rights to royalties from four development-stage therapies. The deal aims to enhance Royalty Pharma's portfolio and supports MorphoSys’s growth strategy.
Royalty Pharma (RPRX) reported strong Q1 2021 results, with GAAP net cash from operations rising 12% to $526 million and total revenues up 14% to $573 million. Adjusted Cash Receipts surged 37% to $524 million, driven by growth in its cystic fibrosis and oncology portfolios. The company announced new royalty transactions totaling $787 million, including $582 million in upfront payments. Royalty Pharma raised its 2021 Adjusted Cash Receipts guidance to $1,940-$1,980 million, reflecting positive business momentum and portfolio expansion.
Royalty Pharma plc (Nasdaq: RPRX) will participate in three investor conferences in May 2021: the Bank of America 2021 Healthcare Conference on May 12, the Truist Securities Life Sciences Summit on May 20, and the UBS Global Healthcare Virtual Conference on May 24. All events will be accessible via the company’s Events page, and webcasts will be archived for at least thirty days.
Royalty Pharma is a leading buyer of biopharmaceutical royalties, funding innovation in the industry and holding royalties on over 45 commercial products.
Royalty Pharma (Nasdaq: RPRX) will report its first quarter 2021 financial results on May 11, 2021, before U.S. markets open. A conference call is scheduled for the same day at 8:00 a.m. ET, accessible via phone or live webcast on the company’s website. Royalty Pharma, established in 1996, is the largest buyer of biopharmaceutical royalties, collaborating with a variety of innovators and funding late-stage clinical trials. The company owns royalties from over 45 commercial products, contributing to its strong industry presence.
Royalty Pharma (Nasdaq: RPRX) announced a collaboration with MSCI Inc. to create new thematic indexes focused on innovation in the life sciences, specifically targeting virology and oncology. This partnership will leverage Royalty Pharma's expertise in medical conditions and clinical trials to assist MSCI in developing index methodologies. The new indexes aim to capture performance metrics of companies delivering advanced therapeutic treatments. The launch is expected later this year, showcasing Royalty Pharma's commitment to monetizing its intellectual capital in life sciences.
The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved a dividend payment of $0.17 per class A share for the second quarter of 2021. This dividend will be paid on June 15, 2021, to shareholders on record as of May 20, 2021. Royalty Pharma is recognized as the largest purchaser of biopharmaceutical royalties and plays a significant role in funding innovation in the biopharmaceutical sector, partnering with a range of companies to enhance their product launches and clinical trials.
Royalty Pharma has acquired Dicerna's royalty interest in OXLUMO for $180 million upfront and up to $60 million in sales-based milestones. OXLUMO, approved for treating primary hyperoxaluria type 1, is marketed by Alnylam Pharmaceuticals. This deal will extend Dicerna's cash runway into 2024, enhancing its ability to fund clinical operations, including the development of its lead candidate, nedosiran. Both companies highlight the innovative nature of RNAi therapeutics as a significant focus of this transaction.
Dicerna Pharmaceuticals (Nasdaq: DRNA) has agreed to sell its royalty interest in OXLUMO™ to Royalty Pharma (Nasdaq: RPRX) for an upfront payment of $180 million, plus potential sales-based milestones of up to $60 million. OXLUMO is FDA and EMA approved for treating primary hyperoxaluria type 1 and marketed by Alnylam Pharmaceuticals. This transaction is expected to extend Dicerna's cash runway into 2024, supporting ongoing clinical plans. The deal reflects Dicerna's commitment to addressing unmet medical needs in rare diseases, specifically primary hyperoxaluria.
Royalty Pharma (RPRX) has acquired royalty interests in Cabometyx and Cometriq from GlaxoSmithKline (GSK) for an upfront payment of $342 million, plus up to $50 million contingent on future regulatory approvals for prostate and lung cancer. Cabometyx is already approved for advanced renal cell carcinoma and hepatocellular carcinoma. In 2020, sales of Cabometyx were $742 million, and Cometriq's sales were €289 million. GSK retains a 3% royalty on worldwide net sales of cabozantinib products, while Royalty Pharma will receive royalties in non-U.S. markets and U.S. royalties through September 2026.
The Board of Directors of Royalty Pharma (Nasdaq: RPRX) has appointed Henry A. Fernandez as Lead Independent Director. Fernandez, CEO of MSCI, will also serve on the Audit Committee. CEO Pablo Legorreta highlighted Fernandez's leadership and business acumen, noting the expected benefits for Royalty Pharma's governance and operations. Fernandez expressed his commitment to maintaining strong oversight in his new role. Royalty Pharma, established in 1996, is the largest buyer of biopharmaceutical royalties and funds innovation in the industry.
FAQ
What is the current stock price of Royalty Pharma Plc (RPRX)?
What is the market cap of Royalty Pharma Plc (RPRX)?
